Jump to content
Crime Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Presently, there are more than 10 approved gene therapies; over 465 product<Roots>


Encouraging clinical results across various metabolic, hematological and ophthalmic disorders have inspired research groups across the world to focus their efforts on the development of novel gene editing therapies. In fact, the gene therapy pipeline has evolved significantly over the past few years, with three products being approved in 2019 alone; namely Beperminogene perplasmid (AnGes), ZOLGENSMA® (AveXis) and ZYNTEGLO™ (bluebird bio). Further, there are multiple pipeline candidates in mid to late-stage (phase II and above) trials that are anticipated to enter the market over the next 5-10 years.

 

To order this 670+ page report, which features 190+ figures and 340+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html

 

The USD 11.6 billion (by 2030) financial opportunity within the gene therapy market has been analyzed across the following segments:

§  Key therapeutic areas

§  Autoimmune disorders

§  Cardiovascular diseases

§  Genetic disorders

§  Hematological disorders

§  Metabolic disorders

§  Ophthalmic disorders

§  Oncological disorders

§  Others

 

§  Type of vector

§  Adeno associated virus

§  Adenovirus

§  Herpes simplex virus type 1

§  Lentivirus

§  Plasmid DNA

§  Retrovirus

§  Vaccinia Virus

 

§  Type of therapy

§  Ex vivo

§  In vivo

 

§  Type of gene modification

§  Gene augmentation

§  Immunotherapy

§  Oncolytic therapy

§  Others

 

§  Route of administration

§  Intraarticular

§  Intracerebellar

§  Intramuscular

§  Intradermal

§  Intravenous

§  Intravitreal

§  Intravesical

§  Subretinal

§  Others

 

§  Key geographical regions

§  North America

§  Europe

§  Asia-Pacific

 

The Gene Therapy Market (3rd Edition), 2019-2030 report features the following companies, which we identified to be key players in this domain:

§  Advantagene

§  Advaxis

§  BioMarin

§  bluebird bio

§  FKD Therapies

§  Freeline Therapeutics

§  GenSight Biologics

§  Gradalis

§  Inovio Pharmaceuticals

§  Marsala Biotech

§  Orchard Therapeutics

§  Pfizer

§  Sarepta Therapeutics

§  Spark Therapeutics

§  Tocagen

§  Transgene

§  uniQure Biopharma

§  VBL Therapeutics

§  ViroMed

 

Table of Contents

 

1. Preface

 

2. Executive Summary

 

3. Introduction

 

4. Gene Delivery Vectors

 

5. Regulatory Landscape and Reimbursement Scenario

 

6. Competitive Landscape

 

7. Marketed Gene Therapies

 

8. Key Commercialization Strategies

 

9. Late Stage (Phase II/III and Above) Gene Therapies

 

10. Emerging Technologies

 

11. Promising Therapeutics Areas

 

12. Patent Analysis

 

13. Mergers and Acquisitions

 

14. Funding and Investment Analysis

 

15. Cost Price Analysis

 

16. Big Pharma Players: Analysis of Gene Therapy Related Initiatives

 

17. Market Forecast and Opportunity Analysis

 

18. Vector Manufacturing

 

19. Case Study: Gene Therapy Supply Chain

 

20. Conclusion

 

21. Interview Transcripts

 

22. Appendix 1: Tabulated Data

 

23. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/gene-therapy-market-3rd-edition-2019-2030/268.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...